Support AlterNet
Do you value the information you're getting from AlterNet? Please show your support with a tax-deductible donation.
Feedback
Tell us how we're doing.
Can Exercise Come in a Pill?
Corporate Accountability and WorkPlace:
Today's Economic Crisis in Historical Perspective
Democracy and Elections:
More Unfinished 2008 Election Business: Verifiable Vote Counts
Steven Rosenfeld
DrugReporter:
A New Approach to Drugs Would Save New York Hundreds of Millions of Dollars
Gabriel Sayegh
Election 2008:
Franken Lawyer: "We Are Going To Win"
Sam Stein
Environment:
Forget the Polar Bears -- The Climate Crisis Is About All of Us
George Monbiot
ForeignPolicy:
Obama Needs to Make a Clean Break on Latin America
Mark Weisbrot
Health and Wellness:
Obama's Health Care Reform Plan Is Based on the Clintons' Failed 1990s Model
Marie Cocco
Hurricane Katrina:
From the Bayou to Baghdad: Mission Not Accomplished
Amy Goodman
Immigration:
Immigrant Rights Signed Away?
Jennifer Lee Koh, Esq.
Media and Technology:
Born Digital: Understanding the First Generation of Digital Natives
Doron Taussig
Movie Mix:
Love Bites: What Sexy Vampires Tell Us About Our Culture
Sarah Seltzer
Reproductive Justice and Gender:
The Hymen Mystique
Carole Roye
Rights and Liberties:
Ban the Cluster Bomb
Brian Cook
Sex and Relationships:
Sex Ed for Seniors
Sue Katz
War on Iraq:
The Dilemma of Foreign Prisoners in Iraq
Ma'ad Fayad
Water:
Corporate Water Abusers Should Not Be Trusted As Stewards of the World's Water
Wenonah Hauter
The timing couldn't have been better.
Salk Institute molecular biologist Ronald Evans debuted the results of a metabolic wonder drug that could mimic exercise, increase endurance and double fat-burning muscle just in time for the Olympics.
Exercisers could lose their treadmills, predicted health reporters, couch potatoes could lose their guilt -- and Olympic athletes could, well, cheat.
In an article in the journal Cell titled AMPK and PPAR Agonists Are Exercise Mimetics, Evans, a professor at the Howard Hughes Medical Institute, and 12 colleagues write that they have identified the "muscle endurance gene signature" and "molecular crosstalk" of two drugs that can actually reprogram muscle, in some cases, without exercise.
One drug, GW1516, developed but abandoned by GlaxoSmithKline because of toxic side effects, improved the endurance of mice that exercised by 77 percent and increased fat-burning "slow twitch" muscle fibers by 38 percent.
The other drug, AICAR, similar to the body's food energy nucleotide, adenosine monophosphate (AMP), and licensed by Schering-Plough Corp. for prevention of a surgical complication (at least until this month's stock bounce anticipating new "uses"), improved endurance in mice that did not exercise by 44 percent.
The changes seen in the lab were not "cosmetic," like the muscle building of steroids.
Rather, both drugs alter metabolism at the genetic level by acting upon PPAR-delta, a gene-controlling protein that produces the slow-twitch, fat-burning muscle fibers associated with endurance athletes, versus fast-twitch, sugar-burning fibers.
"This is not just a free lunch," Evans told the New York Times. "It's pushing your genome toward a more enhanced genetic tone that impacts metabolism and muscle function. So instead of inheriting a great set-point, you are using a drug to move your own genetics to a more activated metabolic state."
Happy Abs Forever?
While the promise of an Ectomorph Nation filled with lean, muscular bodies always opens Wall Street ears and wallets, the 46-year-old La Jolla, Calif.-based Salk Institute for Biological Sciences is not as enamored with lab-to-commercialization "technology transfer" as many pharma-supported institutions are.
Two-thirds of its approximately $90 million annual budget comes from federal funds -- the study published in Cell was supported by the Howard Hughes Medical Institute, the Hillblom Foundation and the National Institutes of Health -- and it penned its first partnership with a for-profit company, Paris-based Ipsen, only this year.
Nor is Evans likely a pharma favorite after publishing the results of a Salk mice study in Nature Medicine last year that found that long-term use of GlaxoSmithKline's Avandia in the treatment of type 2 diabetes "may cause osteoporosis due to both increased bone resorption and decreased bone formation." Oops.
See more stories tagged with: exercise pill, diet drugs, gw1516, aicar
Martha Rosenberg is a columnist and cartoonist who frequently writes about the impact of the pharmaceutical, food and gun industries on public health. A former medical copywriter, her work has appeared in the Boston Globe, San Francisco Chronicle, Los Angeles Times, Chicago Tribune, on the BBC and in the original National Lampoon.
Liked this story? Get top stories in your inbox each week from AlterNet! Sign up now »